InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Goldman Sachs 2025 U.S. Financial Services Conference December 9, 2025 1:00 PM ESTCompany ParticipantsNavid Mahmoodzadegan ...

The company, which sells software that helps users practice important conversations, last week announced a $40 million round, ...

Gov Hyacinth Iormem Alia of Benue State has said that he is determined to fix the broken Benue, some indigenes believed him ...

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...

Discusses Strategic Portfolio Update and Leadership Transition December 8, 2025 9:00 AM ESTCompany ParticipantsJohn Nypaver - ...

IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS ...

The company’s financing sources and maturity profile are illustrated in the following chart: A notable positive development was the reduction in the average interest rate to 4.0% at the end of Q3 2025 ...